Article Text
Abstract
Information is usually supposed to be a prerequisite for people making decisions on whether or not to participate in a clinical trial. Previously conducted studies and research ethics scandals indicate that participants have sometimes lacked important pieces of information. Over the past few decades the quantity of information believed to be adequate has increased significantly, and in some instances a new maxim seems to be in place: the more information, the better the ethics in terms of respecting a participant’s autonomy. The authors hypothesise that the dose-response curve from pharmacology or toxicology serves as a model to illustrate that a large amount of written information does not equal optimality. Using the curve as a pedagogical analogy when teaching ethics to students in clinical sciences, and also in engaging in dialogue with research institutions, may promote reflection on how to adjust information in relation to the preferences of individual participants, thereby transgressing the maxim that more information means better ethics.
- clinical research
- informed consent
- participants’ perceptions
- pedagogical model
- information
Statistics from Altmetric.com
Footnotes
Read the full text or download the PDF:
Other content recommended for you
- An empirical study on the preferred size of the participant information sheet in research
- Cross-sectional assessment of patient attitudes towards participation in clinical trials: does making results publicly available matter?
- Evaluating the impact of a SIMPlified LaYered consent process on recruitment of potential participants to the Staphylococcus aureus Network Adaptive Platform trial: study protocol for a multicentre pragmatic nested randomised clinical trial (SIMPLY-SNAP trial)
- Patients' perceptions of information provided in clinical trials
- Supporting positive experiences and sustained participation in clinical trials: looking beyond information provision
- Decision aids for randomised controlled trials: a qualitative exploration of stakeholders’ views
- Streamlining the Clinical Research Enterprise
- Return of participant-level clinical trial results to participants: pilot of a simplified centralised approach
- From protection to entitlement: selecting research subjects for early phase clinical trials involving breakthrough therapies
- Engaging African ancestry participants in SLE clinical trials